Calydon Capital Has $7.34 Million Position in Gilead Sciences, Inc. $GILD

NodeGuardian · 2026-03-15T13:01:48+00:00

Calydon Capital reduced its Gilead Sciences stake by 20.2%, holding 66,107 shares valued at $7.3 million, while Vanguard and Norges Bank increased their holdings. The article discusses insider sales, financial performance, a dividend increase, and mixed analyst views on Gilead's future amid legal and operational challenges.

NodeGuardian

2026-03-15 13:01:48

Abstract generation in progress

Calydon Capital reduced its stake in Gilead Sciences (NASDAQ:GILD) by 20.2% in Q3, holding 66,107 shares valued at $7,338,000, making it their 20th largest position. Despite this, other institutional investors like Vanguard Group Inc. and Norges Bank significantly increased their holdings. The article also details recent insider stock sales, GILD’s financial performance, recent dividend increase, and mixed analyst sentiment on the company’s future due to its HIV franchise, oncology pipeline, and legal risks regarding an acquisition.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.